Literature DB >> 1362155

Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract.

S Naito1, N Sakamoto, S Kotoh, K Goto, T Matsumoto, J Kumazawa.   

Abstract

The expression of a multidrug-resistant (MDR) gene product, P-glycoprotein, was examined immunohistochemically in 41 transitional cell carcinomas (TCCs) of the urinary tract. In 23 of these, chemosensitivity to adriamycin (ADM) and vinblastine (VBL) was also assessed by a microtiter succinate dehydrogenase inhibition test and the correlation between the expression of P-glycoprotein and MDR phenotype was investigated. P-glycoprotein was detected in 13 (72.2%) of the 18 untreated TCCs of the upper urinary tract (UUT), 6 (31.6%) of the 19 untreated TCCs of the bladder, and all of the 4 TCCs treated with M-VAC chemotherapy, respectively. Fourteen (87.5%) of the 16 TCCs with a positive expression of P-glycoprotein were resistant to ADM and VBL, whereas all of the 4 TCCs sensitive to both drugs were negative in the expression of P-glycoprotein. The succinate dehydrogenase activity of TCCs with a positive expression of P-glycoprotein was significantly higher than that of TCCs with a negative expression of P-glycoprotein (P < 0.05). Thus, there was a good correlation between the expression of P-glycoprotein and MDR phenotype in the chemosensitivity test. These results suggest that intrinsic MDR exists in some TCCs of the urinary tract, particularly UUT, and that the immunohistochemical investigation of P-glycoprotein may be useful for predicting the MDR phenotype in TCCs of the urinary tract.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362155     DOI: 10.1159/000474745

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

Review 1.  Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.

Authors:  Homayoun Zargar; Jonathan Aning; Joseph Ischia; Alan So; Peter Black
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

2.  Establishment and characterization of a multidrug-resistant human bladder carcinoma cell line RT112/D21.

Authors:  O Seemann; M Muscheck; M Siegsmund; H Pilch; C T Nebe; J Rassweiler; P Alken
Journal:  Urol Res       Date:  1995

3.  Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group.

Authors:  S Naito; T Ueda; S Kotoh; A Iguchi; K Sagiyama; Y Hiratsuka; Y Osada; A Ariyoshi; T Omoto; J Kumazawa
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

5.  Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay.

Authors:  S C Clifford; D J Thomas; D E Neal; J Lunec
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

6.  Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.

Authors:  S Hasegawa; T Abe; S Naito; S Kotoh; J Kumazawa; D R Hipfner; R G Deeley; S P Cole; M Kuwano
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

7.  Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.

Authors:  S Naito; S Hasegawa; A Yokomizo; H Koga; S Kotoh; M Kuwano; J Kumazawa
Journal:  Jpn J Cancer Res       Date:  1995-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.